© 2024 Western New York Public Broadcasting Association

140 Lower Terrace
Buffalo, NY 14202

Mailing Address:
Horizons Plaza P.O. Box 1263
Buffalo, NY 14240-1263

Buffalo Toronto Public Media | Phone 716-845-7000
WBFO Newsroom | Phone: 716-845-7040
Your NPR Station
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Donate Today Banner

The State Of Care For Perinatal And Postpartum Depression

There's only one postpartum depression medication currently approved by the FDA. And while it's known to be extremely effective, access is limited.
There's only one postpartum depression medication currently approved by the FDA. And while it's known to be extremely effective, access is limited.

Nearly one in seven people who give birth experience postpartum depression.

Right now, there’s only one PPD medication, called brexanolone, currently approved by the FDA. While it’s known to be extremely effective, access is very limited.

But a revolution in treating perinatal and postpartum depression may be underway.

Earlier this summer, researchers published promising Phase 3 trial results of a new medication called zuranolone.

From Time:

We talk with experts about the current landscape of treatment for perinatal and postpartum depression and what FDA approval of zuranolone could mean.

Copyright 2021 WAMU 88.5

Kathryn Fink
Kathryn Fink is a producer with NPR's All Things Considered.